Morgan Stanley Initiates Coverage On Contineum Therapeutics with Overweight Rating, Announces Price Target of $25
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley has initiated coverage on Contineum Therapeutics (CTNM) with an Overweight rating and set a price target of $25. This move by a major financial institution could signal confidence in CTNM's future performance.
April 30, 2024 | 9:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley initiated coverage on Contineum Therapeutics with an Overweight rating and a price target of $25, indicating a positive outlook on the stock.
The initiation of coverage by Morgan Stanley, a major financial institution, with an Overweight rating and a significant price target of $25, suggests a strong bullish stance on CTNM. This could lead to increased investor interest and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100